Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

Core Insights - Esperion is participating in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET [1] - The company is focused on developing and commercializing FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular disease [2] - Esperion is advancing its next-generation program targeting ATP citrate lyase inhibitors (ACLYi) to create highly potent and specific inhibitors [2][3] Company Overview - Esperion Therapeutics is a commercial-stage biopharmaceutical company addressing unmet medical needs in cardiovascular health [2] - The company has conducted the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients to support its medications [2] - Esperion is evolving into a leading global biopharmaceutical company through commercial execution and international partnerships [3]